What it is
Cortexin is a peptide preparation extracted from animal cerebral cortex, used as a medicine in Russia. It is not a single molecule: a 2018 review in the Korsakov neurology journal groups it with "peptide hydrolysates derived from animal brain" and traces its proposed effects — on oxidative stress, inflammation and the enzyme caspase-8 — to "a variety of neuropeptides" in the mixture (Gulyaeva, PMID 30499504). Because it is a mixture, it has no sequence, formula or molecular weight of its own.
| Property | Value | Source |
|---|---|---|
| Type | Mixture of peptides from animal brain cortex | PMID 30499504 |
| How it is given | Intramuscular; an intravenous form was tested in 2025 | PMIDs 42133422, 41524350 |
| Typical trial course | 10 mg a day for 10 days | PMIDs 42133422, 41782536 |
| Defined relative | Cortagen, Ala-Glu-Asp-Pro, designed from its amino-acid analysis | PMID 15159690 |
Its closest relative in kind is Cerebrolysin, a pig-brain peptide preparation with trials outside Russia. Short synthetic peptides from the same Russian tradition include Semax and Pinealon.
What its trials compared
PubMed has 70 records with "cortexin" in the title (2026-11-19), most in the Russian journal Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. The four largest randomised studies whose abstracts were read:
| Trial | People | What Cortexin was compared with | Reported result |
|---|---|---|---|
| Fedin et al. 2025 (PMID 41524350) | 490, acute ischaemic stroke | Cortexin by the other route — IV v IM, double-dummy placebo | mRS 0–2 at day 90: 93.6% v 86.5%; NIHSS fell 3.93 v 3.72; MMSE p = 0.249 |
| Fedin et al. 2018 (PMID 30335070) | 189, chronic cerebral ischaemia | 20 mg v 10 mg v basic treatment only | "Dose-dependent effect" on neurological symptoms, asthenia, sleep |
| DIACORT 2026 (PMID 42133422) | 110, type 2 diabetes complications | Base treatment (glycine, B vitamins) alone | MoCA ×1.2; HbA1c 7.3% v 7.8%; 5 adverse events, 3 v 2 |
| Schastnyy 2026 (PMID 41782536) | 98, depressive disorder | Antidepressants alone | Larger MADRS fall and more "significant" self-rated improvement (p = 0.001) |
The point the summaries skip: the largest trial gave Cortexin to every patient. It was designed to show that the intravenous form is no worse than the intramuscular one — the placebo was only there to keep both groups blinded to the route. It shows the two forms behave alike; it cannot show either works better than no Cortexin. The diabetes and depression trials compare Cortexin added to standard care with standard care alone, and their abstracts describe no placebo injection, so patients and assessors may have known who received the extra drug.
Animal work is broader. In rats with blocked brain arteries or narrowed carotids, Cortexin at 1 or 3 mg/kg for 10 days reduced damaged tissue and improved behavioural tests, alongside Cerebrolysin and Actovegin, and a radiolabelled dose crossed the blood–brain barrier in mice (Kurkin et al. 2021, PLoS One, PMID 34260655). Two of that paper's authors list Pharm-Holding CJSC, St Petersburg, as their affiliation.
What is not established
- An effect against placebo in a large, independent trial. None was found; no Cortexin study is registered on ClinicalTrials.gov (2026-11-19).
- Which peptides in the mixture do the work, and whether the composition is the same from batch to batch — the abstracts read do not report a characterisation.
- Results outside Russia. The clinical records read are all from Russian centres; the few international-journal papers are laboratory or animal studies.
- Registration details. The entry did not open the Russian state drug register; the trial reports describe it as a medicinal product.
Where it stands
Cortexin is a brain-derived peptide mixture with a sizeable Russian clinical literature built mostly on add-on and open comparisons. Decisions about stroke, cognition or depression treatment belong to a doctor; this entry records what the compound is and what its studies measured.
Sources opened 2026-11-19: PubMed E-utilities (title search; abstracts of PMIDs 42133422, 41782536, 41524350, 30499504, 30335070, 34260655); ClinicalTrials.gov API v2; Drugs@FDA via openFDA.
